MannKind (MNKD) Leerink Global Healthcare Conference 2026 summary

Strategic focus and business evolution

• Transitioned from a single-product company to a diversified portfolio through acquisitions and internal development, notably the scPharmaceuticals acquisition in Q4, which accelerated revenue diversification and integration efforts.

• Emphasis on controlling more revenue streams, with a shift from reliance on royalties to direct product revenues, aiming for 70% of revenue under company control by year-end.

• Focused on multiple growth drivers: Afrezza pediatric launch, FUROSCIX® auto-injector, and the nintedanib program, with expectations for double-digit growth in Tyvaso DPI royalties.

• Several regulatory milestones anticipated, including two FDA approvals and a phase II trial kickoff, positioning for a busy and transformative year.

• Integration of scPharmaceuticals has already resulted in FUROSCIX® and Afrezza revenues surpassing royalty streams in Q4, highlighting successful diversification.

Product and pipeline updates

• FUROSCIX® targets significant hospital and community opportunities, with expanded sales force and upcoming auto-injector expected to drive further growth; $110–$120 million revenue guidance for the year, excluding auto-injector upside.

• Increased field rep investment expected to yield productivity ramp in Q2, setting up for stronger Q3–Q4 performance, especially with auto-injector launch.

• Auto-injector could significantly reduce COGS by up to 70%, improving margins and enabling reinvestment; conversion strategy between on-body and auto-injector will be finalized closer to launch.

• Afrezza shifting from profitability to growth mode, leveraging positive pediatric data, label changes, and new ADA guidelines to target 10–30% pediatric market share, with potential $300–$500 million future revenue.

• Nintedanib (201 program) progressing through phase I in IPF patients, with early data showing promising tolerability and lung concentration; phase II to start in Q2, aiming for improved tolerability over oral formulations.

Financial and operational outlook

• 2024 is positioned as an investment year, balancing commercial launches and R&D with a strong balance sheet and positive operating cash flow.

• Paid off convertible debt stub, maintaining a five-year term loan due 2030, and confident in ability to fund launches and pipeline advancement.

• Management and board demonstrated confidence through insider buying following recent stock volatility, emphasizing undervalued assets and long-term IP protection.

• Company expects to remain cash flow neutral to positive in 2024, with investments expected to pay off in subsequent years.